Reply to: "Comment on 'Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors'".
Private practice, Saint Helena, California. Electronic address: karyduncan@comcast.net.
Karynne O
KO
Duncan
Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Sciences University, Portland, Oregon.
Kevin L
KL
Winthrop
D001691:Biological Therapy / Q000009:adverse effects*; D003141:Communicable Diseases / Q000150:complications* / Q000175:diagnosis*; D006801:Humans; D012871:Skin Diseases / Q000150:complications* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha